After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Cobenfy, which comes in capsule form ... chief commercialization officer for Bristol Myers Squibb, which will distribute the drug. Psychiatrists anticipate the drug could help more people to ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

The most common are nausea, vomiting and indigestion. In contrast to the weight gain seen with other schizophrenia drugs, ...

Bristol Myers (BMY) Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY in ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research ... and growth opportunities such as Cobenfy. While these products have shown promising ...